|
|
 |
|
Viewing report
|
|
|
|
Bacterial Infections: An Epidemiological Overview
Datamonitor, Jan 2003, Pages: 88
The antibacterial market is one of high value, representing an area of substantial interest for novel products. The causative pathogens, site of infection and epidemiology of disease can all have an impact on drug efficacy and need to be fully understood before appropriate product development and positioning can be achieved.
Scope:
- Epidemiology of bacterial infections by site of infection, causative pathogen and location of acquisition and treatment, whether community or hospital
- Examination of the pathogens that are the most frequently isolated and discusses which age and gender groups are at greatest risk of infection
- Full coverage of the following infections: respiratory, urinary tract, intra abdominal, bone, CNS, endocarditis, skin and soft tissue and bloodstream
Report Highlights:
An aging population, childhood immunization and an increased number of immunocompromised patients has changed the epidemiology of bacterial infections. This new focus will drive future antibacterial product development and application.
The increased incidence of hospital treated bacterial infections, combined with the severity of such infections, results in high value antibacterial treatment and offers significant opportunity for novel product development and market growth.
Following the introduction of pediatric immunization, the incidence of infections has decreased. The potential for product development in these fields has shifted to the elderly population.
Reasons to Purchase:
- Understand the epidemiology of bacterial infections
- Refocus product development away from the waning community market
- Concentrate on opportunities for product development and application in the aging population
Customers who bought this item also bought
Bacterial Infections: An Epidemiological Overview
Stakeholder Opinions: Nosocomial Infections - The Need for New Gram-negative Drugs
Stakeholder Opinions: Community Acquired Respiratory Tract Infections - Room for Ketek?
Market Dynamics 2001: Bacterial Infections
Stakeholder Opinions: Skin and Soft Tissue Infections
Urinary Tract Infections: Growing Resistance Rates bring Opportunities for Both New and Old Drugs
Drugs of Tomorrow 2001: Bacterial Infections
Stakeholder Opinions: Skin Infections - Where In The Antibacterial Lifecycle?
Stakeholder Opinions: Urinary Tract Infections - Ciprofloxacin Leads the Way
Infections Bacterial Infections
Stakeholder Insight: Respiratory Tract Infections in the USA - The Demise of Narrow-Spectrum Antibiotics
Infections Urinary Tract Infections
|
|
|
|
